한글목차

이 보고서는 북미와 유럽의 12명의 KOL(Key Opinion Leader)의 견해를 바탕으로 비소세포폐암(NSCLC) 표적 치료의 진화하는 상황을 상세히 분석합니다. 주요 내용은 EGFR 변이 비소세포폐암에서 타그리소(Taglisso)의 사용이 여러 3상 임상시험을 통해 재정의되고 있으며, 어려운 독성 프로파일에도 불구하고 틈새 환자군 외의 환자군에서 리브레반트(Rybrevant)의 사용이 확대되고 있고, HER2 변이 비소세포폐암에서 엔허투(Enhertu)의 사용이 제한적이지만 증가하고 있는 점 등을 들 수 있습니다.

이 보고서는 비소세포폐암 시장을 조사 분석하여 미충족 수요와 시장의 새로운 동향을 다루고 현재와 미래의 치료 경로를 종합적으로 평가합니다.

보고서에서 다루는 주요 브랜드

기업

AbbVie, Amgen, Novartis, Lilly, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Genmab, Merck Group, Blueprint, Merus, Johnson & Johnson, Hutchmed, Rigel Pharmaceuticals, Taiho Pharmaceutical, Xcovery, Cullinan Therapeutics, Dizal Pharmaceutical

목차

주요 요약

현재와 향후 치료 알고리즘

조사 목적

EGFR, HER2 억제제

• 승인된 의약품
  • Tagrisso(osimertinib, AstraZeneca)
  • Rybrevant(amivantamab-vmjw, Genmab/Johnson & Johnson), Lazcluze/Leclaza(lazertinib, Johnson & Johnson)
• 파이프라인약
  • Zipalertinib(Cullinan Therapeutics/Taiho Pharmaceutical), Sunvozertinib(Dizal Pharmaceutical), Zongertinib(Boehringer Ingelheim), Zenocutuzumab(Merus)

항체약물접합체

• 승인된 의약품
  • Enhertu(trastuzumab deruxtecan, Daiichi Sankyo/AstraZeneca)
• 파이프라인약
  • Datopotamab deruxtecan(Daiichi Sankyo/AstraZeneca), Sacituzumab tirumotecan(Merck & Co.), Patritumab deruxtecan(Daiichi Sankyo/Merck & Co.), Telisotuzumab vedotin(AbbVie)

ALK 억제제

• 승인된 의약품
  • Alecensa(alectinib, Roche), Alunbrig(brigatinib, Takeda), Lorbrena/Lorviqua(lorlatinib, Pfizer), Zykadia(ceritinib, Novartis)
• 파이프라인약
  • Ensartinib(Xcovery)

KRAS 억제제

• 승인된 의약품
  • Krazati(adagrasib, Bristol Myers Squibb), Lumakras/Lumykras(sotorasib, Amgen)
• 파이프라인약
  • Olomorasib(Lilly), MK-1084(Merck & Co), Divarasib(Roche)

MET 억제제

• 승인된 의약품
  • Tabrecta(capmatinib, Novartis), Tepmetko((tepotinib, Merck Group)
• 파이프라인약
  • Savolitinib(AstraZeneca/HUTCHMED)

RET 억제제

• 승인된 의약품
  • Gavreto(pralsetinib, Rigel Pharmaceuticals/Blueprint Medicines), Retevmo/Retsevmo(selpercatinib, Lilly)

ROS 억제제

• 승인된 의약품
  • Augtyro(repotrectinib, Bristol Myers Squibb)

BRAF 억제제

• 승인된 의약품
  • Braftovi(encorafenib, Pfizer), Mektovi(binimetinib, Pfizer), Tafinlar(dabrafenib, Novartis), Mekinist(trametinib, Novartis)

기타 작용기서

• 승인된 의약품
  • Xalkori(crizotinib, Pfizer)

향후 치료 동향

• 중요한 견해 요약

부록

KOL의 세부 정보

영문목차

This report provides an in-depth analysis of the evolving landscape of targeted therapies for non-small cell lung cancer (NSCLC), based on insights from 12 key opinion leaders (KOLs) from North America and Europe. Key findings include the redefinition of Tagrisso's use in EGFR-mutated NSCLC through multiple Phase III studies, the expansion of Rybrevant's application beyond niche populations despite its challenging toxicity profile, and the limited but growing uptake of Enhertu in HER2 mutant NSCLC. The report offers a comprehensive review of current and future treatment pathways, addressing unmet needs and emerging trends in the NSCLC market.

Key brands covered in this report:

Key questions answered:

• How is the use of Tagrisso expected to evolve in the treatment of EGFRm NSCLC?
• What are the potential therapies for second-line treatment in patients resistant to third-generation EGFR-TKIs?
• How will Rybrevant's use change with new data and regulatory approvals?
• What impact will the approval of Enhertu for HER2-mutant NSCLC have on its uptake?
• Can pipeline HER2-targeting therapies like zongertinib offer competitive advantages over existing treatments?
• How will new data from studies like CROWN and ALINA affect treatment practices for ALK-positive NSCLC?
• What are the prospects for new targeted therapies for KRAS, MET, RET, ROS1, and BRAF mutations in NSCLC?
• How confident are KOLs in the impact of ADCs currently in development on the treatment paradigm?

Companies:

AbbVie, Amgen, Novartis, Lilly, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Genmab, Merck Group, Blueprint, Merus, Johnson & Johnson, Hutchmed, Rigel Pharmaceuticals, Taiho Pharmaceutical, Xcovery, Cullinan Therapeutics, Dizal Pharmaceutical.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

EGFR and HER2 inhibitors

• Approved drugs
  • Tagrisso (osimertinib; AstraZeneca)
  • Rybrevant (amivantamab-vmjw; Genmab/Johnson & Johnson) and Lazcluze/Leclaza (lazertinib; Johnson & Johnson)
• Pipeline drugs
  • Zipalertinib (Cullinan Therapeutics/Taiho Pharmaceutical); Sunvozertinib (Dizal Pharmaceutical); Zongertinib (Boehringer Ingelheim); Zenocutuzumab (Merus)

Antibody-drug conjugates

• Approved drugs
  • Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca)
• Pipeline drugs
  • Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca); Sacituzumab tirumotecan (Merck & Co.); Patritumab deruxtecan (Daiichi Sankyo/Merck & Co.); Telisotuzumab vedotin (AbbVie)

ALK inhibitors

• Approved drugs
  • Alecensa (alectinib; Roche); Alunbrig (brigatinib; Takeda); Lorbrena/Lorviqua (lorlatinib; Pfizer); Zykadia (ceritinib; Novartis)
• Pipeline drugs
  • Ensartinib (Xcovery)

KRAS inhibitors

• Approved drugs
  • Krazati (adagrasib; Bristol Myers Squibb) and Lumakras/Lumykras (sotorasib; Amgen)
• Pipeline drugs
  • Olomorasib (Lilly); MK-1084 (Merck & Co.); Divarasib (Roche)

MET inhibitors

• Approved drugs
  • Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group)
• Pipeline drugs
  • Savolitinib (AstraZeneca/HUTCHMED)

RET inhibitors

• Approved drugs
  • Gavreto (pralsetinib; Rigel Pharmaceuticals/Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly)

ROS inhibitors

• Approved drugs
  • Augtyro (repotrectinib; Bristol Myers Squibb)

BRAF inhibitors

• Approved drugs
  • Braftovi (encorafenib; Pfizer) and Mektovi (binimetinib; Pfizer); Tafinlar (dabrafenib; Novartis) and Mekinist (trametinib; Novartis)

Other mechanisms of action

• Approved drugs
  • Xalkori (crizotinib; Pfizer)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins